Image pharmaphorum Editor R&D Does the answer to advancing rare disease treatment lie in r... What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population. R&D Why VCs fell in love with pharma R&D in 2021 For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things. R&D Emerging technologies that are changing the way healthcare i... Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses. R&D Medical Informatics in Rare Disease – the bridge between two... Rare diseases bring with them a multitude of challenges for those affected, their relatives and care providers. Load more results
R&D Does the answer to advancing rare disease treatment lie in r... What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population.
R&D Why VCs fell in love with pharma R&D in 2021 For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
R&D Emerging technologies that are changing the way healthcare i... Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses.
R&D Medical Informatics in Rare Disease – the bridge between two... Rare diseases bring with them a multitude of challenges for those affected, their relatives and care providers.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
